Bellicum Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 39

Bellicum Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Bellicum Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Bellicum Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Bellicum Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Bellicum Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bellicum Pharmaceuticals, Inc. - Brief Bellicum Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bellicum Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bellicum Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bellicum Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bellicum Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bellicum Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bellicum Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bellicum Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bellicum Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Bellicum Pharmaceuticals, Inc.; Bellicum Pharmaceuticals, Inc. - Key Therapeutics; Bellicum Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Bellicum Pharmaceuticals, Inc. - News; Bellicum Pharmaceuticals, Inc. - Latest Updates; Bellicum Pharmaceuticals, Inc. - Pipeline; Bellicum Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Bellicum Pharmaceuticals, Inc. Snapshot
Bellicum Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Bellicum Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Bellicum Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Bellicum Pharmaceuticals, Inc. – Pipeline Products Glance
Bellicum Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Bellicum Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Bellicum Pharmaceuticals, Inc. – Drug Profiles
BPX-101
Product Description
Mechanism of Action
R&D Progress
BPX-101 + AP1903
Product Description
Mechanism of Action
R&D Progress
CaspaCIDE ASC
Product Description
Mechanism of Action
R&D Progress
CaspaCIDe DLI
Product Description
Mechanism of Action
R&D Progress
iCD40/TLR Vaccine
Product Description
Mechanism of Action
R&D Progress
iCD40/TLR/Ag Vaccine
Product Description
Mechanism of Action
R&D Progress
Bellicum Pharmaceuticals, Inc. – Pipeline Analysis
Bellicum Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Bellicum Pharmaceuticals, Inc. - Pipeline Products By Target
Bellicum Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Bellicum Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Bellicum Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 27, 2009: Bellicum Pharmaceuticals Announces $4.5 Million In New Funding
Apr 19, 2010: Bellicum Presents Interim Phase I/II Results Of BPX-101 For Treatment Of mCRPC
Feb 18, 2011: Bellicum Announces Presentation Of Phase I/II Safety And Efficacy Data For BPX-101 At Genitourinary Cancers Symposium
Feb 18, 2011: Clinical Responses Demonstrated In Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine
Aug 06, 2009: Bellicum Pharmaceuticals Announces Initiation Of Phase I/II Clinical Trial Of Novel Vaccine For Patients With Advanced Prostate Cancer
Financial Deals Landscape
Bellicum Pharmaceuticals, Inc., Deals Summary
Bellicum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Bellicum Pharmaceuticals Secures $3 Million In Series B Venture Financing
Bellicum Pharmaceutical Secures $4.5 Million In Series A Financing
Bellicum Pharmaceuticals Secures $2.3 Million In Seed Round Of Financing
Licensing Agreements
ARIAD Pharmaceuticals Expands Licensing Agreement With Bellicum Pharmaceuticals
ARIAD Enters Into An Agreement With Bellicum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Bellicum Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Bellicum Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Bellicum Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Bellicum Pharmaceuticals, Inc. - Phase II, H2 2011
Bellicum Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Bellicum Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Bellicum Pharmaceuticals, Inc., Deals Summary
Bellicum Pharmaceuticals Secures $3 Million In Series B Venture Financing
Bellicum Pharmaceutical Secures $4.5 Million In Series A Financing
Bellicum Pharmaceuticals Secures $2.3 Million In Seed Round Of Financing
ARIAD Pharmaceuticals Expands Licensing Agreement With Bellicum Pharmaceuticals
ARIAD Enters Into An Agreement With Bellicum

List of Figures
Bellicum Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Bellicum Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Bellicum Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Bellicum Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Idenix Pharmaceuticals, Inc.
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• Scientific Games Corporation - Company Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution